Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Targeting of Crosstalk Between Tumor and Tumor Microenvironment by Β-D Mannuronic Acid (M2000) in Murine Breast Cancer Model Publisher Pubmed



Hosseini F1 ; Hassannia H2 ; Mahdianshakib A2 ; Jadidiniaragh F3, 4 ; Enderami SE5 ; Fattahi M2, 6 ; Anissian A7 ; Mirshafiey A2 ; Kokhaei P1, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Cancer Research Center and Department of Immunology, Semnan University of Medical Sciences, Semnan, Iran
  2. 2. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  4. 4. Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
  5. 5. Department of Molecular Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
  6. 6. Shiraz institute for cancer research, Shiraz, University of Medical Sciences, Shiraz, Iran
  7. 7. Department of Veterinary Medicine, Islamic Azad University, Abhar, Abhar branch, Iran
  8. 8. Department of Oncology-Pathology, Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Institutet, Stockholm, Sweden

Source: Cancer Medicine Published:2017


Abstract

Metastasis is the main cause of death in breast cancer patients. Inflammatory processes following crosstalk between tumor cells and tumor microenvironment play an important role in progression and metastasis of cancer. Hence, targeting of these interactions may represent a novel promising strategy for breast cancer therapy. So, we investigated the effects of β-D mannuronic acid (BDM), a new antiinflammatory agent, on 4T1 breast cancer cell line both in vitro and in vivo. Proliferation assays revealed low-cytotoxic effect of BDM on 4T1 cells. However, BDM reduced activity of MMP-2, MMP-9 and significantly decreased the adhesion of 4T1 cells to extracellular matrix (ECM) in a dose-dependent manner. The in vivo results demonstrated that BDM strongly inhibits tumor growth and increases lifespan as compared with control mice. The decrease in tumor mass was associated with decreased metastasis, recruitment, and frequency of inflammatory cells in tumor tissue. Our preclinical findings demonstrated that BDM therapy not only prevents formation of chronic inflammatory response but also inhibits crosstalk between tumor cells and their microenvironment, which is associated with reduction of tumor growth and metastasis arrest. Our data imply the use of BDM therapy in future clinical trials to open a new horizon for breast cancer therapy. © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Experts (# of related papers)
Other Related Docs
49. Β-D-Mannuronic Acid (M2000) As a Landmark in Pharmacology, Current Drug Discovery Technologies (2021)